Despite the variety of antibiotics currently available, bacterial infections remain a significant and growing medical problem. Many bacterial infections are serious and/or require hospitalization and treatment with injectable antibiotics.
Among the most common bacterial infections are those caused by Gram-positive bacteria, which include staphylococci, streptococci and enterococci. Gram-positive infections are often serious and life-threatening. The need for more effective antibiotics is particularly acute because many Gram-positive strains, particularly many staphylococci, have become resistant to currently available antibiotics. Of particular note are infections due to methicillin-resistant Staphylococcus aureus (commonly known as MRSA). Drug resistance is especially common in hospital-acquired infections.
Antibiotic Product Candidate — TD-1792
TD-1792 is an investigational heterodimer antibiotic that combines the aspects of both glycopeptide and cephalosporin antibiotic mechanisms into a single molecule. The goal of the TD-1792 clinical program is to develop a next-generation antibiotic for the treatment of serious infections caused by MRSA.
In October 2012, Theravance entered into a development and commercialization agreement with R-Pharm for TD-1792. Theravance granted exclusive development and commercialization rights in the Russian Federation, Ukraine, the other members of the Commonwealth of Independent States, and Georgia.